(Q36201667)

12 August 2017

1 reference

title

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies (English)

1 reference

12 August 2017

11

Eric Van Cutsem

0 references

Josep Tabernero Caturla

2

object named as

Josep Tabernero

1 reference

12 August 2017

12

Alison Layton

1 reference

12 August 2017

Siegfried Segaert

1

1 reference

12 August 2017

Olivier Chosidow

3

1 reference

12 August 2017

Thomas Dirschka

4

1 reference

12 August 2017

Joern Elsner

5

1 reference

12 August 2017

Luca Mancini

6

1 reference

12 August 2017

Tim Maughan

7

1 reference

12 August 2017

Jean-Fran Ois Morere

8

1 reference

12 August 2017

Armando Santoro

9

1 reference

12 August 2017

Alberto Sobrero

10

1 reference

12 August 2017

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

8

1 reference

12 August 2017

599-606

1 reference

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

HER1/EGFR targeting: refining the strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

Comparative safety of tetracycline, minocycline, and doxycycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1610-0387.2005.05058.X

10.1111/J.1610-0387.2005.05058.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference